深圳和美妇儿科医院怎么样

——深圳和美妇儿科医院，15年7月7日在香港正式挂牌上市（港股代码：01509），简称“和美医疗”，深圳和美妇儿科医院为海内外女性、儿童提供优质医疗服务和健康管理高品质、更安全的医疗机构。

——2011年10月，和美医院首次通过国际医疗卫生机构联合委员会（JCI）认证，成为深圳首家JCI认证的高端妇儿科医院。2014年10月，医院再次以高分通过第五版JCI认证复审。2017年11月15日，深圳和美妇儿科医院顺利通过JCI第六版新标复审。

——和美医院采用与美国同步的医疗安全保障体系和治疗系统，领先的医疗技术和管理模式帮助客户获得安全、绿色医疗。和美提倡以外用药物、物理疗法治疗疾病，用行为医学调理亚健康和慢性疾病，减少抗生素的使用，拒绝过度治疗等医疗方式。

Shenzhen HarMoniCare Women&Children's Hospital, affiliated with HarMoniCare Medical Holding Limited, is the largest private maternity hospital in China. On July 7,2015, the corporation was officially registered on the Hong Kong Stock Exchange (Hong Kong stock code 01509). Shenzhen HarMoniCare Women&Children's Hospital provides high-quality health care and health management services for women and children from China and abroad.

In October,2011, HarMoniCare passed the initial accreditation survey by Joint Commission International(JCI), becoming the first JCI-accredited hospital in Shenzhen. In October,2014,HarMoniCare Shenzhen Women and Children's Hospital again sailed through the second accreditation survey besed on the newly-published fifth edition edition JCI standards with flying colors，In November 15, 2017, HarMoniCare Shenzhen Women and Children's hospital were successfully reexamined by the new JCI Sixth Edition.

HarMoniCare Shenzhen Women and Children's Hospital adopts and advocates an American patient safety and care system, which is the world's leading model of medical technology and management, providing safe and green care for customers. HarMoniCare advocates treatment with topically-applied medication and physiotherapy treatment office disease, and improvement of patients' sub-health status and noncommunicable diseases through behavioral medical intervention. HarMoniCare strictly follows recommendations for the appropriate prescription of antibiotics and is committed to reducing